Creative Medical Technology (NASDAQ:CELZ) Upgraded by Wall Street Zen to “Hold” Rating

Creative Medical Technology (NASDAQ:CELZ) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

A number of other equities analysts have also recently commented on the stock. Zacks Research raised shares of Creative Medical Technology to a “hold” rating in a research note on Tuesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Creative Medical Technology in a report on Monday. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Creative Medical Technology currently has a consensus rating of “Reduce”.

Creative Medical Technology Stock Up 5.4%

Shares of NASDAQ CELZ opened at $2.34 on Friday. The stock’s 50-day simple moving average is $3.25 and its two-hundred day simple moving average is $2.98. Creative Medical Technology has a twelve month low of $1.69 and a twelve month high of $6.90. The firm has a market capitalization of $6.04 million, a P/E ratio of -0.80 and a beta of 2.06.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings data on Friday, November 7th. The company reported ($0.48) EPS for the quarter, hitting the consensus estimate of ($0.48). As a group, research analysts anticipate that Creative Medical Technology will post -3.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Armistice Capital LLC purchased a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 148,000 shares of the company’s stock, valued at approximately $321,000. Armistice Capital LLC owned about 3.38% of Creative Medical Technology at the end of the most recent reporting period. 1.42% of the stock is currently owned by institutional investors.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.